BR112021020265A2 - Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo - Google Patents

Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo

Info

Publication number
BR112021020265A2
BR112021020265A2 BR112021020265A BR112021020265A BR112021020265A2 BR 112021020265 A2 BR112021020265 A2 BR 112021020265A2 BR 112021020265 A BR112021020265 A BR 112021020265A BR 112021020265 A BR112021020265 A BR 112021020265A BR 112021020265 A2 BR112021020265 A2 BR 112021020265A2
Authority
BR
Brazil
Prior art keywords
hematologic malignancy
treating
binding
subject
diabody
Prior art date
Application number
BR112021020265A
Other languages
English (en)
Inventor
Ian Lent
Kenneth Davidson Jan
Marc Wigginton Jon
Krishnan Sampathkumar
Froman Alderson Ralph
La Motte-Mohs Ross
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of BR112021020265A2 publication Critical patent/BR112021020265A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo. a presente invenção é direcionada a um regime de dosagem para administrar um diacorpo bispecífico cd123 x cd3 para pacientes com uma malignidade hematológica, tal como leucemia mieloide aguda (aml) ou síndrome mielodisplástica (mds). a presente invenção também é direcionada a um regime de dosagem para administrar um diacorpo bispecífico cd123 x cd3 em combinação com uma molécula capaz de ligar pd-1 ou um ligante natural de pd-1 (uma molécula de ligação de pd-1 ou de ligante de pd-1) a pacientes com uma malignidade hematológica, tal como leucemia mieloide aguda (aml) ou síndrome mielodisplástica (mds). a invenção diz respeito, particularmente, ao uso de tais regimes para administrar o diacorpo bispecífico cd123 x cd3 de sequência otimizada, dart-a, que é capaz da ligação simultânea a cd123 e cd3.]
BR112021020265A 2019-04-10 2020-04-08 Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo BR112021020265A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962831979P 2019-04-10 2019-04-10
US201962831969P 2019-04-10 2019-04-10
US201962929401P 2019-11-01 2019-11-01
US201962929381P 2019-11-01 2019-11-01
US202063001388P 2020-03-29 2020-03-29
PCT/US2020/027140 WO2020210277A1 (en) 2019-04-10 2020-04-08 Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies

Publications (1)

Publication Number Publication Date
BR112021020265A2 true BR112021020265A2 (pt) 2022-01-11

Family

ID=72751774

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020265A BR112021020265A2 (pt) 2019-04-10 2020-04-08 Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo

Country Status (13)

Country Link
US (1) US20220213203A1 (pt)
EP (1) EP3953391A1 (pt)
JP (1) JP2022526640A (pt)
KR (1) KR20210149807A (pt)
CN (1) CN113728009A (pt)
AU (1) AU2020272734A1 (pt)
BR (1) BR112021020265A2 (pt)
CA (1) CA3136255A1 (pt)
IL (1) IL287095A (pt)
MX (1) MX2021012263A (pt)
SG (1) SG11202111192TA (pt)
TW (1) TW202104263A (pt)
WO (1) WO2020210277A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022276523A1 (en) * 2021-05-21 2024-01-18 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
WO2023012367A1 (en) * 2021-08-06 2023-02-09 Universität Basel Discernible cell surface protein variants for use in cell therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2778334A1 (en) * 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES

Also Published As

Publication number Publication date
IL287095A (en) 2021-12-01
US20220213203A1 (en) 2022-07-07
CN113728009A (zh) 2021-11-30
WO2020210277A1 (en) 2020-10-15
AU2020272734A1 (en) 2021-11-18
KR20210149807A (ko) 2021-12-09
CA3136255A1 (en) 2020-10-15
SG11202111192TA (en) 2021-11-29
TW202104263A (zh) 2021-02-01
EP3953391A1 (en) 2022-02-16
JP2022526640A (ja) 2022-05-25
MX2021012263A (es) 2022-01-06

Similar Documents

Publication Publication Date Title
BR112021020265A2 (pt) Método para tratar uma malignidade hematológica e molécula de ligação cd123 x cd3 para o uso no tratamento de uma malignidade hematológica de um indivíduo
MX2022004370A (es) Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
Zanardi et al. Better together: targeted combination therapies in breast cancer
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
Krause et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC
RU2016122232A (ru) Комбинированная терапия на основе антитела к cd20 и ингибитора втк
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
MX2020012755A (es) Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
CL2022000495A1 (es) Formulaciones farmacéuticas y regímenes de dosificación para proteínas de unión multiespecíficas que se unen a her2, nkg2d y cd16 para el tratamiento del cáncer
MX2021004868A (es) Diacuerpos cd123 x cd3 biespecificos para el tratamiento de neoplasias hematologicas.
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
MX2022001179A (es) Formulaciones y dosificaciones para la administración de un compuesto que inhibe la proteína mcl1.
MX2022005330A (es) Moleculas de union multiespecificas con scfv en el extremo nterminal.
MX2020012826A (es) Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
BR112016002311A2 (pt) combinações de inibidor de cinase de pim
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
MX2023006937A (es) Compuestos multicíclicos inhibidores de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y sus usos.
BR112016023011A2 (pt) tratamento de câncer gástrico
EA202190102A1 (ru) Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
BR112022004519A2 (pt) Composições que compreendem citisina no tratamento e/ou prevenção de vício em sujeitos em necessidade do mesmo
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
BR112021008679A2 (pt) Métodos para tratar câncer, e composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]